Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Cancers, Free Full-Text

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Rucaparib vs. Investigator choice - Problems with TRITON-3

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer

Metastatic Prostate Cancer

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations

Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer